Integra LifeSciences Holdings Corporation Files Amendment to Registration Statement for Public Offering of Common Stock
PLAINSBORO, N.J.--(BUSINESS WIRE)--July 20, 2001--Integra LifeSciences Holdings Corporation (NASDAQ: IART) today announced that it had filed an amendment to its registration statement on Form S-3 with the Securities and Exchange Commission for a proposed underwritten offering of 3,750,000 shares of Integra common stock, plus an additional 562,500 shares to cover over-allotments, if any.
Integra will issue 3,500,000 shares and up to an additional 500,000 of the over-allotment option shares, if any. Selling shareholders will sell 250,000 shares and up to 62,500 of the over-allotment option shares, if any. Integra plans to use the proceeds of shares sold by it for general corporate purposes, which could include, among other things, acquisition of product lines or companies, repayment of indebtedness, the expansion of sales and marketing, the development of new technologies and increases in working capital.
The offering will be managed by U.S. Bancorp Piper Jaffray Inc. and co-managed by ABN AMRO Rothschild LLC, CIBC World Markets Corp. and Adams, Harkness & Hill, Inc.
The registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This news release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities law of any such state.
When available, a preliminary prospectus may be obtained from U.S. Bancorp Piper Jaffray Inc. at 800 Nicollet Mall, Minneapolis, Minnesota 55402. Requests for a preliminary prospectus may be made by fax to 612/303-1070, and questions may be directed to 612/303-6220.
Integra LifeSciences Holdings Corporation develops, manufactures and markets medical devices, implants and biomaterials primarily used in the treatment of cranial and spinal disorders, soft tissue repair and orthopedics. Integra is a leader in applying the principles of biotechnology to medical devices that improve patients' quality of life. The Company has its corporate headquarters in Plainsboro, New Jersey and has approximately 550 permanent employees.
This news release and the registration statement to which it refers contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking factors in this news release include, but are not limited to, statements concerning the use of proceeds generated from the sale of Integra's securities. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results.
Among other things, changes in the Company's financing needs may affect the use of proceeds generated from the sale of Integra's securities. In addition, the economic, competitive, governmental, technological and other factors identified under the heading "Risk Factors" in the registration statement and in the Business section of Integra's Annual Report on Form 10-K/A for the year ended December 31, 2000 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results. The registration statement may be obtained from the Company through the contacts listed below.
| Source: | Integra LifeSciences Holdings Corporation |
|---|
www.integra-LS.com
--30--jd/ph*
| CONTACT: | Integra LifeSciences Holdings Corporation, Plainsboro |
|---|---|
| John B. Henneman, III, 609/936-2481 | |
| jhenneman@integra-ls.com | |
| or | |
| John Bostjancic, 609/936-2239 | |
| jbostjancic@integra-ls.com | |